Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.65 |
| ▸ | FLT1 | P17948 | 8/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27545981 | 0.90 | EGFR (0.69) | EGFRFLT1FGFR2FLT3KDR | |
| Hydrochloric Acid SCHEMBL7539353 | 0.89 | EGFR (0.67) | EGFRFLT1FGFR2FLT3KDR | |
| SCHEMBL3606262 | 0.84 | EGFR (0.73) | EGFRFLT1KDRERBB2PIK3CA | |
| SCHEMBL7536031 | 0.83 | MKNK1 (0.69) | EGFRFLT1KDRRETERBB2 | |
| Hydrochloric Acid SCHEMBL8593958 | 0.82 | EGFR (0.72) | EGFRFLT1KDRPRKD1 | |
| SCHEMBL7655860 | 0.82 | PRKD1 (0.52) | EGFRFLT1FGFR2FLT3PRKD1 | |
| SCHEMBL8082013 | 0.82 | EGFR (0.74) | EGFRFLT1KDRRETERBB2 | |
| SCHEMBL7537238 | 0.82 | EGFR (0.67) | EGFRFLT1KDRRETERBB2 | |
| SCHEMBL30302541 | 0.81 | FGFR2 (0.56) | EGFRFLT1FGFR2FLT3KDR | |
| SCHEMBL22803328 | 0.81 | FGFR2 (0.56) | EGFRFLT1FGFR2FLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3290666-B2 | — | — | 2002-06-10 | — | — | JP | claimed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | claimed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | claimed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |